Cenmox: Potent Broad-Spectrum Antibiotic for Bacterial Infection Resolution
Cenmox
Cenmox (Amoxicillin) is a high-potency, broad-spectrum aminopenicillin antibiotic designed for the systematic eradication of susceptible bacterial strains. It is formulated to provide reliable, rapid-onset bactericidal activity by inhibiting bacterial cell wall synthesis, leading to osmotic instability and cell lysis. Clinically indicated for a wide array of community-acquired infections, Cenmox remains a first-line therapeutic choice due to its excellent tissue penetration, predictable pharmacokinetics, and well-established safety profile. This product card provides comprehensive information for healthcare professionals to ensure appropriate prescribing and patient counseling.
Features
- Active ingredient: Amoxicillin 500 mg (as trihydrate)
- Pharmacologic class: Beta-lactam antibiotic, Aminopenicillin
- Mechanism of action: Inhibition of transpeptidation in bacterial cell wall synthesis
- Spectrum: Broad-spectrum activity against Gram-positive and Gram-negative aerobes
- Formulation: Film-coated tablets for oral administration
- Bioavailability: Approximately 80% when taken orally, unaffected by gastric pH
- Half-life: ~61.3 minutes; primarily excreted renally unchanged
Benefits
- Rapid bactericidal action reduces bacterial load and alleviates symptoms typically within 48–72 hours
- High oral bioavailability ensures consistent systemic drug levels without need for parenteral administration in most cases
- Broad spectrum coverage targets common pathogens responsible for respiratory, urinary, skin, and ear infections
- Well-tolerated profile with a low incidence of severe adverse effects when used as directed
- Flexible dosing regimen allows for adaptation based on infection severity and renal function
- Proven efficacy in both adult and pediatric populations (dose-adjusted)
Common use
Cenmox is indicated for the treatment of infections caused by susceptible strains of designated microorganisms, including:
- Otitis media (Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes)
- Pharyngitis and tonsillitis (Streptococcus pyogenes)
- Lower respiratory tract infections (S. pneumoniae, H. influenzae, non-penicillinase-producing staphylococci)
- Skin and skin structure infections (S. pyogenes, non-penicillinase-producing staphylococci)
- Genitourinary infections (Escherichia coli, Proteus mirabilis, Enterococcus faecalis)
- Helicobacter pylori eradication (as part of combination therapy)
Dosage and direction
Adults:
- Mild to moderate infections: 500 mg orally every 12 hours or 250 mg every 8 hours
- Severe infections or those caused by less susceptible organisms: 875 mg every 12 hours or 500 mg every 8 hours
Pediatric patients (>3 months, <40 kg):
- 20–45 mg/kg/day orally in divided doses every 8–12 hours, based on infection severity
Administration guidance:
- May be taken with or without food; administration with food may reduce gastrointestinal upset
- Complete the full prescribed course even if symptoms resolve earlier to prevent resistance development
- Adjust dose in patients with severe renal impairment (creatinine clearance <30 mL/min)
Precautions
- Use with caution in patients with mononucleosis due to high incidence of erythematous rash
- Prolonged use may result in fungal or bacterial superinfection, including pseudomembranous colitis
- Periodic assessment of renal, hepatic, and hematopoietic function during prolonged therapy
- False-positive urinary glucose tests may occur with Benedict’s or Fehling’s solutions; use glucose oxidase methods
- Not recommended for treatment of sexually transmitted infections without confirmed susceptibility testing
Contraindications
- History of hypersensitivity to amoxicillin, other penicillins, or beta-lactam antibiotics
- Patients with a history of amoxicillin-associated cholestatic jaundice/hepatic dysfunction
- Concomitant use with disulfiram (within past 2 weeks) due to alcohol content in some suspensions)
- Infectious mononucleosis (due to rash risk)
Possible side effect
Common (≥1%):
- Diarrhea, nausea, vomiting
- Skin rash, urticaria
- Vaginal candidiasis
Less common (<1%):
- Reversible leukopenia, neutropenia, thrombocytopenia
- Elevated liver enzymes
- Black hairy tongue, tooth discoloration (reversible with dental cleaning)
Rare:
- Anaphylaxis, Stevens-Johnson syndrome
- Hemolytic anemia, interstitial nephritis
- Antibiotic-associated colitis (including pseudomembranous colitis)
Drug interaction
- Probenecid: Decreases renal tubular secretion of amoxicillin, increasing blood levels and half-life
- Oral anticoagulants: May potentiate anticoagulant effect; monitor INR
- Allopurinol: Increased incidence of skin rash
- Bacteriostatic antibiotics (e.g., tetracyclines, macrolides): May antagonize bactericidal effect
- Methotrexate: Increased methotrexate serum levels and toxicity risk
- Oral contraceptives: Possible reduced efficacy; advise backup contraception
Missed dose
- Take the missed dose as soon as remembered unless it is almost time for the next scheduled dose
- Do not double the dose to make up for a missed one
- Maintain regular dosing intervals to ensure consistent therapeutic levels
Overdose
- Symptoms: Gastrointestinal distress (nausea, vomiting, diarrhea), crystaluria, hematuria
- Management: Primarily supportive; gastric lavage if recent ingestion; maintain hydration and electrolyte balance
- Hemodialysis may accelerate elimination in cases of significant overdose, particularly in renal impairment
Storage
- Store at controlled room temperature (20°–25°C or 68°–77°F)
- Protect from moisture and light
- Keep container tightly closed
- Discard any unused suspension after 14 days when refrigerated
Disclaimer
This information is intended for healthcare professionals and does not replace clinical judgment. Prescribers should verify susceptibility patterns through local antibiograms. Dosage must be individualized based on infection severity, pathogen susceptibility, and patient characteristics. Cross-sensitivity with cephalosporins may occur in up to 10% of penicillin-sensitive patients. Not for viral infections.
Reviews
“Consistently reliable for community-acquired pneumonia and strep pharyngitis in my practice. Rapid clinical response and generally well-tolerated.” – Dr. A. Reynolds, Infectious Disease Specialist
“Preferred first-line option for pediatric otitis media due to palatability and efficacy. Parent compliance is high with twice-daily dosing.” – Pediatric Partners Group
“Excellent tissue penetration makes it effective for soft tissue infections. I appreciate the predictable pharmacokinetics in most patient populations.” – Dr. L. Chen, Surgeon